Balancing human leukocyte antigen matching, graft source, and other donor characteristics can assure engraftment, limit GVHD and promote immune reconstitution; all to improve HCT outcomes. Fig 1.

Neutrophil recovery was defined as an absolute neutrophil count of at least 500/μL for three consecutive time points. Platelet recovery was defined as a count of 50 000/μL without transfusion support.

Please provide your email address to receive an email when new articles are posted on . Several single-institution studies have demonstrated the safety and efficacy of conditioning with IV busulfan ...

NEW ORLEANS -- A three-drug regimen should be the standard for graft-versus-host disease (GvHD) prophylaxis in blood cancer patients undergoing reduced-intensity conditioning allogeneic hematopoietic ...

Orca-Q, Orca Bio’s second investigational allogeneic T-cell immunotherapy, showed low rates of acute and chronic GvHD, infections and non-relapse mortality with and without GvHD prophylaxis Orca-T ...

The Pearson’s χ 2-test or Fisher’s exact text was used for univariate comparisons of categorical variables. Observation time for acute GVHD was calculated from the date of BMT (day 0) until the date ...

Patients undergoing matched-donor stem cell transplants lived four times longer without episodes of graft-versus-host disease (GVHD) with post-transplant cyclophosphamide-cyclosporin prophylaxis, a ...

A newer regimen was no more effective than an older regimen when both were compared for graft versus host disease (GVHD) prophylaxis in patients who underwent reduced-intensity conditioning followed ...

Prophylactic treatment with low-dose corticosteroids accelerated platelet recovery and significantly decreased the prevalence of acute graft-versus-host disease among high-risk patients undergoing ...

Hematopoietic stem cell transplantation can cure hematologic malignancies. The most significant obstacle to its success is graft vs host disease (GVHD), in which immunocompetent cells from the graft ...

Subgroup analysis revealed a pronounced effect among patients receiving MAC. In this cohort, 6-month grade 2-4 GFS was 35.7% with placebo vs 60.7% with ustekinumab (OR 2.78 for failure; 80% CI, 1.19-6 ...

PTCY offers improved progression-free and overall survival compared to ATG in MDS patients undergoing allo-HSCT. PTCY is associated with lower rates of grade 2 to 4 acute GVHD but has delayed ...